XML 21 R20.htm IDEA: XBRL DOCUMENT v3.20.1
Stock Option Plan and Stock Based Compensation
12 Months Ended
Feb. 29, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Stock Option Plan and Stock Based Compensation

(12) Stock Option Plan and Stock Based Compensation

The Company grants stock options and restricted stock to key executives and managerial employees and non-employee directors. At fiscal year ended 2018, the Company has one stock option plan: the 2004 Long-Term Incentive Plan of Ennis, Inc., as amended and restated as of June 30, 2011, formerly the 1998 Option and Restricted Stock Plan amended and restated as of May 14, 2008 (the “Plan”). The Company has 520,104 shares of unissued common stock reserved under the Plan for issuance. The exercise price of each stock option granted under the Plan equals a referenced price of the Company’s common stock as reported on the New York Stock Exchange (“NYSE”) on the date of grant, and an option’s maximum term is ten years. Stock options and restricted stock may be granted at different times during the year and vest ratably over various periods, from grant date up to five years. The Company uses treasury stock to satisfy option exercises and restricted stock awards.

The Company recognizes compensation expense for stock options and restricted stock grants on a straight-line basis over the requisite service period.  For the years ended 2020, 2019 and 2018, the Company included in selling, general and administrative expenses, compensation expense related to share based compensation of $1.4 million, $1.4 million and $1.3 million, respectively.

Stock Options

The following occurred with respect to the Company’s stock options for each of the three years ended February 29, 2020:

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

Average

 

 

Aggregate

 

 

 

Number

 

 

Average

 

 

Remaining

 

 

Intrinsic

 

 

 

of Shares

 

 

Exercise

 

 

Contractual

 

 

Value(a)

 

 

 

(exact quantity)

 

 

Price

 

 

Life (in years)

 

 

(in thousands)

 

Outstanding at March 1, 2017

 

 

172,496

 

 

$

15.95

 

 

 

4.2

 

 

$

223

 

Granted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Terminated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercised

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at February 28, 2018

 

 

172,496

 

 

$

15.95

 

 

 

3.2

 

 

$

612

 

Granted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Terminated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercised

 

 

(110,906

)

 

 

15.99

 

 

 

 

 

 

 

 

 

Outstanding at February 28, 2019

 

 

61,590

 

 

$

15.88

 

 

 

1.8

 

 

$

327

 

Granted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Terminated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercised

 

 

(61,590

)

 

$

15.88

 

 

 

 

 

 

 

 

 

Outstanding at February 29, 2020

 

 

 

 

 

 

 

 

 

 

 

 

Exercisable at February 29, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

(a)

Intrinsic value is measured as the excess fair market value of the Company’s common stock as reported on the NYSE over the applicable exercise price.

No stock options were granted during fiscal years 2020, 2019 or 2018.   

 

 

A summary of the stock options exercised and tax benefits realized from stock based compensation is presented below for the three fiscal years ended (in thousands):

 

 

 

Fiscal years ended

 

 

 

2020

 

 

2019

 

 

2018

 

Total cash received

 

$

 

 

$

69

 

 

$

 

Total grant-date fair value

 

 

201

 

 

 

345

 

 

 

 

Intrinsic value

 

 

267

 

 

 

534

 

 

 

 

 

The Company had no unvested stock options outstanding at any time during the fiscal year ended February 29, 2020.

 

Restricted Stock

The following occurred with respect to the Company’s restricted stock awards for each of the three fiscal years ended February 29, 2020:

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

Average

 

 

Number of

 

 

Grant Date

 

 

Shares

 

 

Fair Value

 

Outstanding at March 1, 2017

 

166,546

 

 

$

16.35

 

Granted

 

74,900

 

 

 

16.30

 

Terminated

 

 

 

 

 

Vested

 

(88,771

)

 

 

15.90

 

Outstanding at February 28, 2018

 

152,675

 

 

$

16.59

 

Granted

 

83,789

 

 

 

20.54

 

Terminated

 

 

 

 

 

Vested

 

(81,359

)

 

 

16.01

 

Outstanding at February 28, 2019

 

155,105

 

 

$

19.03

 

Granted

 

66,669

 

 

 

20.41

 

Terminated

 

(3,920

)

 

 

17.02

 

Vested

 

(73,928

)

 

 

18.90

 

Outstanding at February 29, 2020

 

143,926

 

 

$

19.79

 

 

As of February 29, 2020, the total remaining unrecognized compensation cost related to unvested restricted stock was approximately $1.7 million. The weighted average remaining requisite service period of the unvested restricted stock awards was 1.5 years.  As of February 29, 2020, the Company’s outstanding restricted stock had an underlying fair value of $2.8 million at date of grant.